GlycoMimetics Inc  

(Public, NASDAQ:GLYC)   Watch this stock  
Find more results for GLYC
+0.84 (3.60%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 22.90 - 24.89
52 week 3.82 - 26.05
Open 23.48
Vol / Avg. 501,783.00/612,602.00
Mkt cap 830.63M
P/E     -
Div/yield     -
EPS -1.24
Shares 34.34M
Beta 3.40
Inst. own 95%
Mar 14, 2018
GlycoMimetics Inc at Cowen Health care Conference - 9:20AM EDT - Add to calendar
Mar 6, 2018
Q4 2017 GlycoMimetics Inc Earnings Call Add to calendar
Dec 19, 2017
GlycoMimetics, Inc. - Special Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -171945.10%
Operating margin - -172505.30%
EBITD margin - -171475.40%
Return on average assets -26.86% -70.03%
Return on average equity -28.47% -83.96%
Employees 42 -
CDP Score - -


9708 Medical Center Dr
ROCKVILLE, MD 20850-3343
United States - Map
+1-240-2431201 (Phone)
+1-240-2431018 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Officers and directors

M. James E. Barrett Ph.D. Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Rachel K. King President, Chief Executive Officer, Co-Founder, Director
Age: 57
Bio & Compensation  - Reuters
John Magnani Ph.D. Co-Founder, Senior Vice President, Chief Scientific Officer, Director
Age: 64
Bio & Compensation  - Reuters
Brian Hahn Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Helen M. Thackray M.D., Senior Vice President - Clinical Development, Chief Medical Officer
Age: 47
Bio & Compensation  - Reuters
Patricia S. Andrews Director
Bio & Compensation  - Reuters
Mark Alan Goldberg M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Daniel M. Junius Independent Director
Age: 64
Bio & Compensation  - Reuters
Scott Koenig M.D., Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Timothy R. Pearson Independent Director
Age: 49
Bio & Compensation  - Reuters